Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

Analyst Ratings

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $83.00 (80.87% upside)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016MizuhoDowngradeBuy -> Neutral$66.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Royal Bank Of CanadaReiterated RatingBuy$78.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016William BlairReiterated RatingOutperform$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Cantor FitzgeraldReiterated RatingBuy$95.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.30$0.07$20.78 million$18.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.57)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115$1.47$1.31$3.41 million$36.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015($0.49)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/17/2014Q314($0.49)($0.65)$2.81 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.37)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.02$0.02$0.02
Q2 20161$0.78$0.78$0.78
Q3 20161$0.93$0.93$0.93
Q4 20161$2.46$2.46$2.46
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateHeadline
07/23/16 07:53 AMEarnings Focus and Crowd Sourced Sentiment Review for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - TGP
07/23/16 07:53 AMLasalle Street Capital Management adds Eagle Pharmaceuticals Inc (EGRX) to its portfolio - TheFounders Daily
07/22/16 07:50 PMIMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 22, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company") ...
07/22/16 03:43 PMThe Law Offices of Howard G. Smith Announces the...
07/22/16 11:13 AMThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals Inc. Investors and Encourages Investors to Contact the Firm - [Business Wire] - Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Eagle Pharmaceuticals Inc. securities between February 23, 2016 and March 18, 2016, inclusive .
07/22/16 10:50 AMAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 22, 2016 / Lundin Law PC (the "Firm") announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company") ...
07/22/16 09:31 AMINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 – EGRX - [GlobeNewswire] - NEW YORK, July 22, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, Inc. between ...
07/22/16 07:59 AMNew Strong Sell Stocks for July 22nd -
07/22/16 06:41 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Expected To Post Sales Of $361.835 - Investor Newswire
07/22/16 06:41 AMHow Analysts Feel About Eagle Pharmaceuticals Inc After Forming Bearish Multiple Bottom Pattern? - Consumer Eagle
07/21/16 03:57 PMINVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1 ... - EIN News (press release)
07/21/16 10:07 AMSHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company") ...
07/21/16 08:30 AMINVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline - [GlobeNewswire] - SAN FRANCISCO, July 21, 2016-- Hagens Berman Sobol Shapiro LLP reminds investors in Eagle Pharmaceuticals, Inc. that the Lead Plaintiff Deadline is August 1, 2016.. If you purchased or otherwise acquired ...
07/21/16 07:17 AMIs $98 Price Target Attainable For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)? - Investor Newswire
07/20/16 04:59 PMJw Asset Management LLC Decreased Stake in Eagle Pharmaceuticals INC (NASDAQ:EGRX) by $3.89 Million as ... - Consumer Eagle
07/20/16 07:15 AMEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 20, 2016 -
07/20/16 06:46 AMEagle Pharmaceuticals Inc's Stock Is Sell After Today's Huge Decline - Consumer Eagle
07/19/16 09:03 PMEquity Roundup: Stock Performance Focus on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Press Telegraph
07/18/16 05:49 PMEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. - EGRX - [GlobeNewswire] - NEW YORK, July 18, 2016-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Eagle Pharmaceuticals, Inc. securities from February ...
07/18/16 03:54 PMStock in Positive Territory for the Quarter: Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) - Engelwood Daily
07/18/16 03:54 PMShare Performance Summary for: Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) - Press Telegraph
07/18/16 11:29 AMIMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. And Reminds Investors with Losses To Contact The Firm - [Business Wire] - Lundin Law PC announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 .
07/18/16 09:19 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:
07/17/16 03:28 PMAre Analysts Bullish Eagle Pharmaceuticals Inc (NASDAQ:EGRX) After Last Week? - Press Telegraph
07/15/16 10:37 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Yearly Sales Target At $429.085 - Investor Newswire
07/15/16 10:37 AMCrowd Rating and Earnings Recap for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Telanagana Press
07/15/16 10:37 AMEagle Pharmaceuticals Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 04:34 PMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm - [Business Wire] - Lundin Law PC announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 .
07/14/16 04:09 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 04:03 PMStrong Sell Calls For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) At 0 - Investor Newswire
07/13/16 04:03 PMEagle Pharmaceuticals Inc (EGRX) Current Analyst Ratings - Fiscal Standard
07/12/16 04:03 PMEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
07/12/16 08:58 AMINVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - [Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc.
07/12/16 08:04 AMTrading Performance and Target Watch for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Press Telegraph
07/11/16 03:47 PMCompany Stock Focus for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Which Way Will Shares Head? - Press Telegraph
07/11/16 03:47 PMNext Weeks Broker Price Targets For Eagle Pharmaceuticals Inc (EGRX) - Fiscal Standard
07/08/16 02:03 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") ...
07/08/16 10:06 AMINVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX - [PR Newswire] - NEW YORK, July 8, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased ...
07/08/16 07:17 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Expected To Post Sales Of $429.085 - Investor Newswire
07/07/16 07:28 PMIMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. . Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 inclusive , are encouraged to contact the Firm prior to the August 1, 2016 lead plaintiff motion deadline.
07/07/16 03:50 PMEagle Pharmaceuticals Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 07:14 AMEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : July 7, 2016 -
07/07/16 06:55 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Expected to Reach Highs Of $98 - Investor Newswire
07/07/16 06:55 AMJw Asset Management LLC Decreased Stake in Eagle Pharmaceuticals INC (NASDAQ:EGRX) by $3.89 Million as ... - Engelwood Daily
07/06/16 03:53 PMEagle Pharmaceuticals Inc. (EGRX): Douglas Braunstein of Hudson Executive Capital Appointed Chairman
07/06/16 08:31 AMEagle Pharmaceuticals Incorporated (NASDAQ:EGRX) Shorted Shares Increased 21.28% After Market Selling - Press Telegraph
07/06/16 08:31 AMCan Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Improve on the Earnings Front? - Engelwood Daily
07/06/16 08:31 AMShare Performance Recap for: Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) - Press Telegraph
07/06/16 08:31 AMStock Rating Watch and Earnings Insight for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Press Telegraph
07/06/16 08:31 AMEagle Pharmaceuticals Inc. (EGRX): Douglas Braunstein of Hudson Executive Capital Appointed Chairman - Insider Monkey (blog)

Social

About Eagle Pharmaceuticals

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection. Argatroban Injection treats thrombosis. Ryanodex treats malignant hyperthermia. Diclofenac sodium and misoprostol delayed-release tablets treat the signs and symptoms of osteoarthritis or rheumatoid arthritis. Docetaxel Injection treats breast cancer, non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck cancer. Its pipeline products include EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute concentrate solution), EP-3102 (bendamustine rapid infusion), EP-6101 (bivalirudin) and EP-5101 (pemetrexed).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $45.89
  • 50 Day Moving Average: $43.27
  • 200 Day Moving Average: $51.20
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $717.54M
  • Beta: 1.24
  • Current Year EPS Consensus Estimate: $4.02 EPS
  • Next Year EPS Consensus Estimate: $5.44 EPS
Additional Links:
Eagle Pharmaceuticals (NASDAQ:EGRX) Chart for Sunday, July, 24, 2016